Machine learning and generative AI combined with causal inference frameworks may strengthen oncology real-world evidence used for regulatory decisions.
A 2026 review in Therapeutic Innovation & Regulatory Science assessed artificial intelligence for real-world evidence in oncology from a statistical perspective for regulatory decisions. It described RWE as limited by data quality, population selection, treatment characterization, outcome assessment, and statistical methodology, and discussed machine learning and generative AI combined with causal inference frameworks as approaches that may address those challenges.
- Impact 30%
- 49
- Evidence 25%
- 95
- Scale 20%
- 35
- Confidence 15%
- 87
- Recency 10%
- 91
Updated Aug 28, 2026 · TRV-2026-0914
ace